Dr. Jagannath on Next-Generation Approaches in Multiple Myeloma

Sundar Jagannath, MD
Published: Monday, Mar 21, 2016



Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses next-generation approaches in multiple myeloma.

Therapeutic options in multiple myeloma are rapidly expanding, says Jagannath. In 2015, 4 new agents were approved by the FDA as treatments for patients with relapsed/refractory multiple myeloma: panobinostat, elotuzumab, daratumumab, and ixazomib.

These agents can be safely used in combination with other existing drugs, he says. At the 2015 ASH Annual Meeting, the results of a study combining lenalidomide, daratumumab, and the checkpoint inhibitor pembrolizumab were presented. This combination was able to put patients who were refractory to currently approved agents into remission, says Jagannath.


Sundar Jagannath, MD, professor of Medicine, Hematology and Medical Oncology, Mount Sinai Hospital, discusses next-generation approaches in multiple myeloma.

Therapeutic options in multiple myeloma are rapidly expanding, says Jagannath. In 2015, 4 new agents were approved by the FDA as treatments for patients with relapsed/refractory multiple myeloma: panobinostat, elotuzumab, daratumumab, and ixazomib.

These agents can be safely used in combination with other existing drugs, he says. At the 2015 ASH Annual Meeting, the results of a study combining lenalidomide, daratumumab, and the checkpoint inhibitor pembrolizumab were presented. This combination was able to put patients who were refractory to currently approved agents into remission, says Jagannath.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x